Altered CD39 and CD73 Expression in Rheumatoid Arthritis : Implications for Disease Activity and Treatment Response
Ortiz, M. Àngels (Institut d'Investigació Biomèdica Sant Pau)
Díaz Torne, César (Institut d'Investigació Biomèdica Sant Pau)
De Agustin, Juan Jose (Hospital Universitari Vall d'Hebron)
Estrada, Paula (Hospital de Sant Joan Despí Moisès Broggi)
Reina, Delia (Hospital de Sant Joan Despí Moisès Broggi)
Hernandez, María Victoria (Hospital Clínic i Provincial de Barcelona)
Sang, Hye (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Zamora, Carlos (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Cantó, Elisabet (Institut d'Investigació Biomèdica Sant Pau)
Corominas, Hèctor (Institut d'Investigació Biomèdica Sant Pau)
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	In rheumatoid arthritis (RA) synovium, ATP, and ADP are released, sparking inflammation. Ectoenzymes CD39 and CD73 metabolize these purine nucleotides, generating anti-inflammatory adenosine. Therefore, dysregulated CD39 and CD73 expression may impact RA development. We assessed CD39 and CD73 expression in peripheral blood from 15 healthy controls (Cs) and 35 RA patients at baseline and after 3 and 6 months of tocilizumab treatment using flow cytometry. Additionally, ectoenzyme expression was examined on cultured T cells to understand activation and IL-6 effects. At baseline, RA patients exhibited a lower CD8 + CD39 − CD73 + cell percentage, which inversely correlated with DAS28. Additionally, they had lower percentages of Treg CD39 + CD73 + and CD39 − CD73 − cells. Good responders tended to have lower B CD39 + CD73 + cell percentages at baseline and 3 months. Additionally, Treg, CD8 + T and B cells inversely correlated with DAS28. T-cell activation increased CD39 and decreased CD73 expression, regardless of IL-6. IL-6 reduced IFNγ-secreting CD4 + T-cell percentage in Cs, but increased the percentage of IFNγ-secreting CD4 + and CD8 + T cells in RA patients. These findings indicate differing CD39 and CD73 expression in RA and Cs, influenced by T-cell activation and IL-6. Correlations between these molecules and RA activity suggest their role in dysregulated inflammation in RA.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	CD39 ; CD73 ; IL-6 ; Rheumatoid arthritis ; Tocilizumab
Published in:	Biomolecules, Vol. 14 (december 2023) , ISSN 2218-273X

DOI: 10.3390/biom14010001
PMID: 38275742

17 p, 3.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles